CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 648 enrolled
Drug / intervention
PS Group +2 moredrug
Likely dose
Prophylactic surfactant administration shortly after delivery (specific agent and dose not specified)AI-extracted
Key inclusion· 4
  • Gestational age 26+0 to 29+6 weeks
  • Imminent delivery
  • Antenatal steroid status known
  • No known lung maturity
Key exclusion· 2
  • Potentially life-threatening congenital anomaly or genetic syndrome
  • Stillborn or Apgar score of 0 at one minute

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00244101
NCT00244101Phase 3Completed

Delivery Room Management of Premature Infants at High Risk of Respiratory Distress Syndrome

Vermont Oxford Network·interventional·Posted Oct 25, 2005·Updated Jan 18, 2023

In Brief

A Phase 3 clinical trial evaluating PS Group, NCPAP Group, and 1 other intervention for Respiratory Distress Syndrome, Newborn. Completed, enrolled 648 participants across 1 site.

Detailed Summary

The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk for respiratory distress syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 25, 2005
Enrollment StartAug 1, 2003
Primary CompletionJun 1, 2009
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 20.7 years ago

Interventions

PS Groupdrug

Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.

NCPAP Groupdevice

Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.

ISX Groupdrug

Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.